Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[18F]F-AraG PET Imaging in SCCHN
NCT03129061Phase 1Completed
- Sponsor
- CellSight Technologies
- Start
- May 2017
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of [18F]fluoro-arabinofuranosyl guanine in head and neck squamous cell carcinoma (HNSCC) (2 cohorts), sponsored by CellSight Technologies. Primary endpoint: Change in VisAcT imaging signal. Started May 2017; status: completed.
02
Drugs
[18F]fluoro-arabinofuranosyl guanine
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT03129061.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03129061.